Emerging Managers

Grishin is the robotics emerging manager you're looking for

Dmitry Grishin, founder of the Grishin Robotics firm, recently raised a $100 million fund and is learning the ins and outs of being a VC

Fund performance: Longitude, Column Group lead emerging managers portfolio at Calpers

The Capital Link Fund shows mixed results, with six of the 11 funds in positive IRR territory as of September 2015

Bullpen Capital aims to raise $75 mln for third fund

Bullpen Capital, an investor in Appboy, FanDuel and SpotHero, has set out to raise $75 million for its third fund, according to a regulatory document.

SGVC raises $50 mln for second fund

SGVC raises $50 mln for second fund

Next World Capital secures more than $122 mln in commitments

San Francisco-based Next World Capital has raised $122.75 million for its second fund, which is targeted at $125 million, according to a regulatory filing. The commitments were raised from 11 investors.

Rethink Education more than halfway to $125 mln target

White Plains, N.Y.-based Rethink Education has raised $67.175 million toward a $125 million targeted second fund, according to a regulatory filing. The filing indicates the firm has raised the commitments from 44 investors. Rethink raised $25 million for its first fund, which closed in 2012, according to Thomson Reuters.

Rethink Education more than halfway to $125 mln target

White Plains, N.Y.-based Rethink Education has raised $67.175 million toward a $125 million targeted second fund, according to a regulatory filing. The filing indicates the firm has raised the commitments from 44 investors. Rethink raised $25 million for its first fund, which closed in 2012, according to Thomson Reuters.

New funds in registration include a handful of China-focused investors

A roundup of firms that have filed their intent to raise new funds or they have reported initial closes

Life sciences-focused venBio raises $315 mln for second fund

San Francisco-based venBio Partners announced it has raised $315 million for its second life science fund, which is anchored by investments from strategic LPs Amgen, Merck and Baxalta. The amount exceeds the $250 million target it set in March 2015, according to a regulatory filing. The firm, which also has an office in New York, typically invests in clinical-stage life science companies with a therapeutic product.